Cargando…

Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody

Invasive fungal infections (IFI) cause devastating morbidity and mortality, with the number of IFIs more than tripling since 1979. Our laboratories were the first to demonstrate that radiolabeled microorganism-specific monoclonal antibodies are highly effective for treatment of experimental fungal,...

Descripción completa

Detalles Bibliográficos
Autores principales: Helal, Muath, Allen, Kevin J. H., van Dijk, Bruce, Nosanchuk, Joshua D., Snead, Elisabeth, Dadachova, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019017/
https://www.ncbi.nlm.nih.gov/pubmed/32117166
http://dx.doi.org/10.3389/fmicb.2020.00147
_version_ 1783497433998688256
author Helal, Muath
Allen, Kevin J. H.
van Dijk, Bruce
Nosanchuk, Joshua D.
Snead, Elisabeth
Dadachova, Ekaterina
author_facet Helal, Muath
Allen, Kevin J. H.
van Dijk, Bruce
Nosanchuk, Joshua D.
Snead, Elisabeth
Dadachova, Ekaterina
author_sort Helal, Muath
collection PubMed
description Invasive fungal infections (IFI) cause devastating morbidity and mortality, with the number of IFIs more than tripling since 1979. Our laboratories were the first to demonstrate that radiolabeled microorganism-specific monoclonal antibodies are highly effective for treatment of experimental fungal, bacterial and viral infections. Later we proposed to utilize surface expressed pan-antigens shared by major IFI-causing pathogens such as beta-glucans as RIT targets. Here we evaluated in vivo RIT targeting beta-glucan in Blastomyces dermatitidis which causes serious infections in immunocompromised and immunocompetent individuals and in companion dogs. B. dermatitidis cells were treated with the 400-2 antibody to (1→3)-β-glucans radiolabeled with the beta-emitter 177Lutetium ((177)Lu) and alpha-emitter 213Bismuth ((213)Bi) and the efficacy of cell kill was determined by colony forming units (CFUs). To determine the antigen-specific localization of the 400-2 antibody in vivo, C57BL6 mice were infected intratracheally with 2 × 10(5) B. dermatitidis cells and given (111)In-400-2 antibody 24 h later. To evaluate the killing of B. dermatitidis cells with RIT, intratracheally infected mice were treated with 150 μCi (213)Bi-400-2 and their lungs analyzed for CFUs 96 h post-infection. (213)Bi-400-2 proved to be more effective in killing B. dermatitidis cells in vitro than (177)Lu-400-2. Three times more (111)In-400-2 accumulated in the lungs of infected mice, than in the non-infected ones. (213)Bi-400-2 lowered the fungal burden in the lungs of infected mice more than 2 logs in comparison with non-treated infected controls. In conclusion, our results demonstrate the ability of an anti-(1-3)-beta-D-glucan antibody armed with an alpha-emitter (213)Bi to selectively kill B. dermatitidis cells in vitro and in vivo. These first in vivo results of the effectiveness of RIT targeting pan-antigens on fungal pathogens warrant further investigation.
format Online
Article
Text
id pubmed-7019017
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70190172020-02-28 Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody Helal, Muath Allen, Kevin J. H. van Dijk, Bruce Nosanchuk, Joshua D. Snead, Elisabeth Dadachova, Ekaterina Front Microbiol Microbiology Invasive fungal infections (IFI) cause devastating morbidity and mortality, with the number of IFIs more than tripling since 1979. Our laboratories were the first to demonstrate that radiolabeled microorganism-specific monoclonal antibodies are highly effective for treatment of experimental fungal, bacterial and viral infections. Later we proposed to utilize surface expressed pan-antigens shared by major IFI-causing pathogens such as beta-glucans as RIT targets. Here we evaluated in vivo RIT targeting beta-glucan in Blastomyces dermatitidis which causes serious infections in immunocompromised and immunocompetent individuals and in companion dogs. B. dermatitidis cells were treated with the 400-2 antibody to (1→3)-β-glucans radiolabeled with the beta-emitter 177Lutetium ((177)Lu) and alpha-emitter 213Bismuth ((213)Bi) and the efficacy of cell kill was determined by colony forming units (CFUs). To determine the antigen-specific localization of the 400-2 antibody in vivo, C57BL6 mice were infected intratracheally with 2 × 10(5) B. dermatitidis cells and given (111)In-400-2 antibody 24 h later. To evaluate the killing of B. dermatitidis cells with RIT, intratracheally infected mice were treated with 150 μCi (213)Bi-400-2 and their lungs analyzed for CFUs 96 h post-infection. (213)Bi-400-2 proved to be more effective in killing B. dermatitidis cells in vitro than (177)Lu-400-2. Three times more (111)In-400-2 accumulated in the lungs of infected mice, than in the non-infected ones. (213)Bi-400-2 lowered the fungal burden in the lungs of infected mice more than 2 logs in comparison with non-treated infected controls. In conclusion, our results demonstrate the ability of an anti-(1-3)-beta-D-glucan antibody armed with an alpha-emitter (213)Bi to selectively kill B. dermatitidis cells in vitro and in vivo. These first in vivo results of the effectiveness of RIT targeting pan-antigens on fungal pathogens warrant further investigation. Frontiers Media S.A. 2020-02-07 /pmc/articles/PMC7019017/ /pubmed/32117166 http://dx.doi.org/10.3389/fmicb.2020.00147 Text en Copyright © 2020 Helal, Allen, van Dijk, Nosanchuk, Snead and Dadachova. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Helal, Muath
Allen, Kevin J. H.
van Dijk, Bruce
Nosanchuk, Joshua D.
Snead, Elisabeth
Dadachova, Ekaterina
Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title_full Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title_fullStr Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title_full_unstemmed Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title_short Radioimmunotherapy of Blastomycosis in a Mouse Model With a (1→3)-β-Glucans Targeting Antibody
title_sort radioimmunotherapy of blastomycosis in a mouse model with a (1→3)-β-glucans targeting antibody
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019017/
https://www.ncbi.nlm.nih.gov/pubmed/32117166
http://dx.doi.org/10.3389/fmicb.2020.00147
work_keys_str_mv AT helalmuath radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody
AT allenkevinjh radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody
AT vandijkbruce radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody
AT nosanchukjoshuad radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody
AT sneadelisabeth radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody
AT dadachovaekaterina radioimmunotherapyofblastomycosisinamousemodelwitha13bglucanstargetingantibody